Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1

Interventions

fludarabine phosphate 58 Cyclophosphamide 54 Epoetin Alfa 43 Cyclosporine 43 Busulfan 43 Peripheral Blood Stem Cell Transplantation 39 Mycophenolic Acid 34 Darbepoetin alfa 33 Antilymphocyte Serum 31 Whole-Body Irradiation 30 Cytarabine 30 Filgrastim 29 Methotrexate 26 Tacrolimus 25 Radiotherapy 25 Melphalan 24 fludarabine 21 Methylprednisolone 17 Cord Blood Stem Cell Transplantation 17 Etoposide 14 Granulocyte Colony-Stimulating Factor 13 Daunorubicin 13 Rivaroxaban 12 apixaban 11 Thiotepa 11 sargramostim 10 epoetin beta 10 Dalteparin 10 eltrombopag 9 Alemtuzumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × betrixaban × Classical hematology × Clear all

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡